Paratek Pharmaceuticals Stock News

BOSTON, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-sa

BOSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-sa

A reader contacted me about a company in his area - Louisiana-Pacific, or "LP", a business that's heavily invested in the timber and building materials area. The company pioneered OSB panels in North

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) insider Randall B. Brenner sold 4,479 shares of Paratek Pharmaceuticals stock in a transaction that occurred on Monday, December 13th. The stock was sold at an average price of $4.42, for a total transaction of $19,797.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which []

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) General Counsel William M. Haskel sold 4,876 shares of the companys stock in a transaction dated Monday, December 13th. The shares were sold at an average price of $4.42, for a total transaction of $21,551.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is []

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) General Counsel William M. Haskel sold 17,178 shares of Paratek Pharmaceuticals stock in a transaction on Wednesday, December 15th. The shares were sold at an average price of $4.27, for a total value of $73,350.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is []

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) insider Randall B. Brenner sold 15,780 shares of the firms stock in a transaction on Wednesday, December 15th. The shares were sold at an average price of $4.27, for a total value of $67,380.60. The sale was disclosed in a legal filing with the SEC, which is available through this link. []

Paratek earns $6 million milestone payment from Zai Lab Paratek earns $6 million milestone payment from Zai Lab

BOSTON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-sa

Paratek Pharmaceuticals (NASDAQ:PRTK) and Tricida (NASDAQ:TCDA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends. Risk and Volatility Paratek Pharmaceuticals has a beta of 1.5, suggesting that its stock price is []

Northern Trust Corp lowered its holdings in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) by 1.1% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 481,062 shares of the specialty pharmaceutical companys stock after selling 5,228 shares during the period. Northern Trust Corp owned approximately 0.99% of []

Equities research analysts expect Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) to report $33.52 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for Paratek Pharmaceuticals earnings, with the lowest sales estimate coming in at $31.64 million and the highest estimate coming in at $35.39 million. Paratek Pharmaceuticals reported sales of $16.02 million []

Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q3 2021 Results - Earnings Call Transcript

-- Potential $1 Billion Addressable Market Opportunity in the United States -- Potential $1 Billion Addressable Market Opportunity in the United States

BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi